Erratum to “AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity”

Mori, Nobuhiro; Kodama, Toshiyuki; Sakai, Atsushi; Suzuki, Tadakiyo; Sugihara, T.T.; Yamaguchi, Seika; Nishijima, Toshio; Aoki, Akiko; Toriya, Minoru; Kasai, Magosaburo; Hatano, Satoru; Kitagawa, Meiko; Yoshimi, Akira; Nishimura, Kenichi

doi:10.1016/s0924-8579(02)00013-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Np Derived Drugs Launched Since 19981

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97,98,[105][106][107][108][109][110] Ceftizoxime alapivoxil (AS-924) 2, which is a prodrug of the second generation cephalosporin ceftizoxime, is in preregistration in Japan and was developed by Kyoto Yakuhin and licensed to Asahi Kasei Pharma. 109,111,112 Basilea Pharmaceutica is developing the cephalosporin ceftobiprole (BAL-5788, Ro-65-5788) 3, a prodrug of BAL-9141 (Ro-63-9141), as a broad spectrum antibiotic with activity against both Gram positive and negative bacteria. Faropenem daloxate (SUN-208, BAY-56-6824) 6 is an orally active, penem-type b-lactam that was licensed to Replidyne by Daiichi Suntory Pharma in August 2004.…”

Section: Np Derived Drugs Launched Since 1998mentioning

confidence: 99%